68results about How to "Dissolution complete" patented technology

The invention discloses active tea cream high in extraction rate and complete in beneficial component preservation and a preparation method thereof, and belongs to the technical field of tea leaf deep processing. The active tea cream comprises the following components by weight: 30 to 50 % of tea polyphenol, 20 to 30 % of tea polysaccharide, 6 to 10 % of free amino acid and 3 to 4 % of caffeine, and the sum of the weight percentage of the components is not larger than 100 %. The preparation method comprises processes of stocking, extracting, dirt-removing, condensing and forming: placing pulverized tea leaves in an extracting jar, adding an extractive at the temperature of 40 to 60 DEG C according to the feed-liquid ratio of 1: (10 to 15), extracting once or twice, extracting for 10 to 20 min every time, and collecting low temperature extract liquid; adding an extractive at the temperature of 60 to 80 DEG C according to the feed-liquid ratio of 1: (5 to 10), extracting once or twice, extracting for 10 to 20 min every time, and collecting high temperature extract liquid, mixing the extract liquid gained after double extraction according to certain proportion to gain total extract liquid, and gaining the active tea cream after dirt-removing, condensing and drying. The preparation method is high in extraction rate, complete in beneficial component preservation and simple in manufacturing technology; the prepared active tea cream is rich in nutrition, strong in fragrance and mellow in taste, and has a good market popularizing value.

The invention discloses a medicine compound containing candesartan cilexetil, and a preparation method thereof; and the medicine compound improves the stability of the base medicine and improves the dissolution rate of the medicine by preparing solid dispersion. The medicine compound is used for curing primary hypertension.

The invention discloses a powder forging and molding method for preparing a porous amorphous alloy block material. The method comprises the following steps of: after respectively sieving amorphous powder and a powdered NaCl pore-forming agent, proportionally weighing the two components according to a porosity requirement; after uniformly mixing the components by a material mixer, carrying out sheathing, degassing and enveloping; carrying out heating and heat preservation on the sheathed and enveloped powder in a cold liquid phase area (Tg-Tx) for 5-15 minutes; forging and molding according to a set forging ratio, maintaining pressure for 30-90s and then forging; removing sheaths by adopting a machining method; and removing the pore forming agent by a water dissolving method to obtain the porous amorphous alloy block material. The method is simple and easy to apply, the prepared porous amorphous alloy material has the characteristics of controlled porosity, opening structure, uniform pore size distribution, and the like; meanwhile, the structural behavior of the powder can also be maintained. The dissolution of the pore forming agent is environmentally friendly, and the pore forming agent can be repeatedly used after treated.

The invention discloses a Febuxostat tablet. The Febuxostat tablet comprises a tablet core and a coating, wherein the tablet core comprises the following components in weight percentage: 5-30 percent of Febuxostat, 15-60 percent of filler, 1-20 percent of disintegrating agent, 0.1-5 percent of surface active agent, 0.1-8 percent of lubricant and a right amount of adhesive. According to the Febuxostat tablet, trough adopting the powerful disintegrating agent within a reasonable proportional region, and meanwhile, through jointly using the surface active agent, the poorly water-soluble drug Febuxostat dissolves out, and further, the dissolvability of the Febuxostat is increased, and the bioavailability of the Febuxostat is improved. Moreover, the Febuxostat tablet is simple in preparation method, controllable in quality and high in stability.

The invention discloses an imatinib mesylate tablet and a preparation method thereof. The imatinib mesylate tablet comprises 8-30% of crospovidone and 8 to 40% of silica. The preparation method comprises the following steps of carrying out granulation of imatinib mesylate and a waterless organic solvent, drying the granules, uniformly mixing the granules, crospovidone, silica, a filler and a lubricant, and carrying out tabletting. The preparation method solves the problem of a slow dissolution rate of a preparation obtained by the prior art.

The invention discloses imatinib mesylate tablet cores comprising, by weight, 20-70% of imatinib mesylate alpha crystalline form, 10-50% of a filling agent, 0-10% of an adhesive, 10-30% of a disintegrant, 0.1-5% of a flow aid, and 0.1-2% of a lubricant. According to the tablet core preparation method, granulation and tabletting are carried out with the formula. The invention also discloses imatinib mesylate coated tablets and a preparation method thereof. The coated tablets comprise, by weight, 95-97% of the imatinib mesylate tablet cores, 0.5-4% of a film forming agent, 0.1-1% of a plasticizer, 0.1-1% of a coloring agent, and 0.1-1% of a lubricant. The preparation method of the coated tablets comprises the steps that the tablet cores are coated, such that the imatinib mesylate coated tablets are prepared. The tablets have the advantages of high dissolution rate and fast release.

The invention relates to a self-microemulsion dutasteride orally-taken preparation and a preparation method thereof. The self-microemulsion composition comprises the following components in percent by weight: 0.05%-0.3% of dutasteride, 5%-75% of oil, 20%-60% of an emulsifier and 4%-50% of a co-emulsifier. After being cured, the self-microemulsion auxiliary materials can be prepared into preparations such as tablets or capsules; after being quickly disintegrated in a stomach, the preparation can be form emulsion drops with average grain size of 10 nm-100 nm in a gastrointestinal tract after being self-microemulsified, so that solubility and dissolution rate of the dutasteride can be improved, and absorption of the dutasteride in the gastrointestinal tract can be promoted.

The invention discloses a powder extrusion forming method for preparing a porous amorphous alloy block material, which comprises: sieving amorphous powder and powder NaCl pore-forming agent respectively, weighing the amorphous powder and powder NaCl pore-forming agent according to porosity requirements, mixing the powder uniformly in a mixer, and sheathing the mixed powder, exhausting air and sealing the sheath; and heating the powder packaged by the sheath in a cold liquid phase area (Tg-Tx), keeping the temperature for 5 to 15 minutes, performing extrusion forming according to a design extrusion ratio, removing the sheath by machining, and removing the pore-forming agent by using a water solution process to obtain the blocky porous amorphous alloy material. The method is simple and easy to implement. The prepared porous amorphous alloy material has the characteristics of controllable porosity, open structure, uniform aperture distribution and the like. Meanwhile, the structural state of the powder can be retained, the dissolution of the pore-forming agent is environmentally-friendly, and the pore-forming can be recycled after processing.

The invention discloses an indissolvable drug oral sustained-release composition, which is especially suitable for low-dose indissolvable drugs. The indissolvable drug oral sustained-release composition comprises sustained-release particles and a gel skeleton, wherein the sustained-release particles comprise an indissolvable drug, an enteric material and a liquid strong adsorption carrier; the gelskeleton comprises a hydrophilic gel skeleton material; and the sustained-release particles are obtained by preparing a suspension from the indissolvable drug and the enteric material and then spraying the suspension onto the liquid strong adsorption carrier. The sustained-release particles are partially wrapped by the gel skeleton to form a multi-sustained-release system technology, the releasetime is prolonged, the preparation process is simple, the efficiency is high, the drug mixing is uniform, and the content loss is less.

The invention discloses a papaya anti-oxidant serum, which comprises cyclodextrin inclusion compound of pawpaw natural antioxidant and carriers accepted in pharmacy. The papaya anti-oxidant serum consists of enzymolysis water extract and alcohol extract of the papaya, in which vitamin C and polyphenols are contained. Vitamin C contained in papaya anti-oxidant serum is no less than 2 milligram per gram, and the total polyphenols calculated in gallic acid is no less than 22 milligram. Therefore, the papaya anti-oxidant serum has the characteristics of high efficiency, durability and stable inoxidizability and easy storage and carrying, can be served as health food to eat, can used as cosmetics, animal food, food or medical mediate, and further can used for preparing antioxidation products; the invention also discloses a preparation method for the papaya anti-oxidant serum, which comprises seven steps of pulping, enzyme digestion, filtering, alcohol extraction, concentration, inclusion and pelletization, so as to be a system for efficiently, sufficiently and completely extracting papaya anti-oxidant, and the antioxidative activity can be effectively preserved.

The invention relates to an extraction method in the technical field of traditional Chinese medicines, in particular to an isatis root pre-treatment method for fermenting extraction of isatis root polysaccharide. The isatis roots are crushed by means of fluid energy milling, so that the isatis root structure can be more fined and extraction of polysaccharide is not affected; by damaging the mechanical supporting wall membrane structures of the isatis roots, polysaccharide can be more fully dissolved in later stage. Steam explosion is carried out for pre-treatment. High-temperature saturated steam quickly permeates into the cell tissues of the isatis roots and component separation and structure change of raw materials are achieved by moment decompression, so that the cell tissues of the isatis roots are damaged; interconnection among fiber bundles is damaged, so that cell walls are broken to form smooth porous structures; the fiber bundles are separated, and the cell walls are broken, so that the functional components wrapped in the fiber bundles or cells are released, the mass transfer ability is obviously reduced, and therefore, a purpose of increasing the polysaccharide extraction ratio is achieved.

The invention discloses anoectochilus roxburghii healthcare baijiu. The anoectochilus roxburghii healthcare baijiu is prepared from, by mass, 800-1500 parts of 40-60 %vol of brewed baijiu, 0.7-1.4 parts of anoectochilus roxburghii, 0.5-1.0 parts of wolfberries, 0.8-1.5 parts of radix glycyrrhizae and 15-30 parts of honey. The invention further discloses a production technology of the anoectochilus roxburghii healthcare baijiu, anoectochilus roxburghii, the wolfberries and radix glycyrrhizae are extracted by adopting the brewed baijiu, and are then subjected to solid-liquid separation to obtain filter liquid, the honey is added into the filter liquid to be homogenized, and then microfiltration is conducted to obtain the anoectochilus roxburghii healthcare baijiu. The anoectochilus roxburghii healthcare baijiu is rich in nutrient substances, remarkable in healthcare effect, the extraction efficiency is high, and the impurity separation is thorough.

The invention belongs to the technical field of medicines, and particularly relates to a levofloxacin tablet composition and a preparation method thereof. The pharmaceutical composition contains levofloxacin, a filling agent, a lubricating agent, a disintegrating agent, an adhesive and oleic acid. The product is high in stability, is dissolved completely, and has higher product quality. The product is easy and feasible to produce and operate, and is suitable for industrial production.

The invention belongs to the field of pharmaceutical preparations, and relates to an oral preparation. The oral preparation is prepared from: (a) a compound shown as a formula (1) or a pharmaceutically-acceptable salt, isomer, solvent compound, hydrate or crystal thereof; and (b) an adsorbent. The invention further relates to a preparation method of the oral preparation and application of the oralpreparation to a medicament for preventing and/or treating hepatitis C. The oral preparation disclosed by the invention can be completely dissolved, is absorbed well in vivo, and has few impurities and high stability. The formula (1) is shown in the description.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an ibuprofen sustained-release capsule and a preparation method thereof. The capsule is prepared by the following steps: enabling ibuprofen and a sustained-release carrier to be prepared into a solid dispersion by a spray drying method, adding a lubricant, performing mixing and performing filling, wherein preferably, the sustained-release carrier is polyacrylic resin polyethylene glycol. The capsule is good in slow release effect, good in process reproducibility and suitable for large-scaleproduction.

The invention discloses a medical composition containing amorphous atorvastatin calcium and a preparation method thereof. By adopting the medical composition, the stability of the medicines is obviously improved, the disintegration speed fastened and the dissolution improved. The medical composition is used for treating high cholesterin lipidemia, can reduce administration dosage, avoids great quantity of medication, enables the blood drug concentration of patients to be smooth and simultaneously increases compliance.

The invention discloses a method for determining the dissolution rate of meisuoshuli tablets. The method comprises the steps that the meisuoshuli tablets are dissolved by taking a phosphate buffer solution with the pH valve of 8.5-8.9 as a dissolution medium to obtain a test solution; absorbancy detection is performed on the test solution, and the dissolution rate of the meisuoshuli tablets is determined on the basis of a result of the absorbancy detection. According to the method, the dissolution rate of the meisuoshuli tablets can be effectively determined, the specificity is high, the needed analysis time is short, the precision and the repeatability are good, and the accuracy is high.

The invention belongs to the technical field of medicines, and in particular relates to a medicinal composition containing fenofibric acid. The medicinal composition contains the fenofibric acid, a filling agent, a disintegrating agent, a lubricating agent, methylcellulose and mannitol granules. The medicinal composition is good in stability, dissolves out completely, and has excellent quality; the production of the medicinal composition is simple and feasible to operate, and the medicinal composition is suitable for industrial production.